Alumis (NASDAQ: ALMS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Alumis reported 15 open-market sales of 119,707 shares ($1.6m) and 40 open-market purchases of 5,815,759 shares ($61.7m), by 12 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 November 2026 | Hardiman Roy C. | Chief Business & Strategy Ofcr | Open-market sale | −652 | $6.52 | 207,094 | Form 4 |
| 2 November 2026 | Schroer John R. | Chief Financial Officer | Open-market sale | −794 | $6.52 | 23,924 | Form 4 |
| 2 November 2026 | Goldstein David M | Chief Scientific Officer | Open-market sale | −629 | $6.52 | 30,341 | Form 4 |
| 2 November 2026 | Drappa Jorn | Chief Medical Officer | Open-market sale | −593 | $6.52 | 56,299 | Form 4 |
| 2 November 2026 | Bradley Mark Christopher | Chief Development Officer | Open-market sale | −623 | $6.52 | 47,910 | Form 4 |
| 2 November 2026 | Pangali Sanam | Chief Legal Officer | Open-market sale | −332 | $6.52 | 9,415 | Form 4 |
| 8 September 2026 | Akkaraju Srinivas | Director | Open-market sale | −48,066 | $10.55 | 4,663,735 | Form 4 |
| 8 September 2026 | Akkaraju Srinivas | Director | Open-market sale | −48,065 | $10.55 | 2,025,493 | Form 4 |
| 8 September 2026 | Akkaraju Srinivas | Director | Open-market purchase | +273,291 | $10.63 | 4,937,026 | Form 4 |
| 8 September 2026 | Akkaraju Srinivas | Director | Open-market purchase | +273,290 | $10.63 | 2,298,783 | Form 4 |
| 4 September 2026 | Akkaraju Srinivas | Director | Open-market purchase | +220,070 | $11.17 | 4,711,801 | Form 4 |
| 4 September 2026 | Akkaraju Srinivas | Director | Open-market purchase | +220,070 | $11.17 | 2,073,558 | Form 4 |
| 3 August 2026 | Hardiman Roy C. | Chief Business & Strategy Ofcr | Open-market sale | −2,692 | $26.37 | 207,746 | Form 4 |
| 3 August 2026 | Schroer John R. | Chief Financial Officer | Open-market sale | −3,282 | $26.37 | 24,718 | Form 4 |
| 3 August 2026 | Goldstein David M | Chief Scientific Officer | Open-market sale | −2,596 | $26.37 | 30,970 | Form 4 |
| 3 August 2026 | Drappa Jorn | Chief Medical Officer | Open-market sale | −2,447 | $26.37 | 56,892 | Form 4 |
| 3 August 2026 | Bradley Mark Christopher | Chief Development Officer | Open-market sale | −2,572 | $26.37 | 48,533 | Form 4 |
| 3 August 2026 | Pangali Sanam | Chief Legal Officer | Open-market sale | −1,364 | $26.37 | 9,747 | Form 4 |
| 6 July 2026 | Pangali Sanam | Chief Legal Officer | Option exercise | +5,000 | $5.06 | 16,111 | Form 4 |
| 6 July 2026 | Pangali Sanam | Chief Legal Officer | Open-market sale | −5,000 | $28.00 | 11,111 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Alumis page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.